Y-Biologics is Korea’s leading R&D biotech company in the field of antibody drug development.

Since establishing Y-Biologics in 2007, our company has focused on the research and development of antibody therapeutics, successfully building antibody platform technologies. Utilizing our excellent and differentiated platform technologies, we are striving to become a leading global antibody drug development company in the field of immuno-oncology & cytokine. Here at Y-Biologics, with our full-cycle antibody development capabilities, we are pursuing full-fledged development of I/O drugs using our bispecific antibody platform. We aim to address unmet medical needs by developing a next-generation immunotherapeutics with higher patient response rates and superior efficacy in comparison to existing I/O drugs.

Y-SERVICE Technologys_Antibody Screening, Protein Expression, Cell Line Development, Analysis Service

1. Antibody Screening (Naive Library Screening, Immune Library Screening, Human Nanobody Screening)
2. Antibody Optimization (Antibody Humanization, Affinity Maturation)
3. Transient Recombinant Protein (Antigen & Antibody) Production using HEK293F, ExpiCHO
4. Stable Cell Line Development using Beacon System (ex. SAFC CHOZN)
5. Analysis Services (Hybridoma Sequencing, Biacore 8K/Octet R8, N-Glycan, Endotoxin Test, etc.)

Y-Biologics

Org chart

Teams

Offices